Your browser doesn't support javascript.
loading
Association between the regular use of vaginal dilators and/or sexual activity and vaginal morbidity in locally advanced cervical cancer survivors - An EMBRACE-I study report.
Kirchheiner, Kathrin; Zaharie, Alexandru; Smet, Stéphanie; Spampinato, Sofia; Chargari, Cyrus; Haie-Meder, Christine; Mahantshetty, Umesh; Segedin, Barbara; Bruheim, Kjersti; Rai, Bhavana; Cooper, Rachel; Van der Steen-Banasik, Elzbieta; Wiebe, Ericka; Pötter, Richard; Sturdza, Alina; Schmid, Maximilian P; Tanderup, Kari; De Leeuw, Astrid; Jürgenliemk-Schulz, Ina M; Nout, Remi A.
Affiliation
  • Kirchheiner K; Department of Radiation Oncology, Comprehensive Cancer Center, Medical University, General Hospital of Vienna, Vienna, Austria. Electronic address: kathrin.kirchheiner@meduniwien.ac.at.
  • Zaharie A; Department of Radiation Oncology, Comprehensive Cancer Center, Medical University, General Hospital of Vienna, Vienna, Austria.
  • Smet S; Department of Radiation Oncology, AZ Turnhout, Turnhout, Belgium; Iridium Cancer Network, Antwerp, Belgium.
  • Spampinato S; Danish Centre for Particle Therapy, Aarhus University Hospital, Aarhus, Denmark; Department of Radiotherapy, Erasmus MC Cancer Institute, University Medical Center, Rotterdam, the Netherlands.
  • Chargari C; Department of Radiotherapy, Gustave-Roussy, Villejuif, France.
  • Haie-Meder C; Department of Radiotherapy, Gustave-Roussy, Villejuif, France.
  • Mahantshetty U; Homi Bhabha Cancer Hospital and Research Centre, Tata Memorial Centre, Mumbai, India.
  • Segedin B; Institute of Oncology Ljubljana, Department of Radiotherapy, Slovenia and University of Ljubljana, Faculty of Medicine, Ljubljana, Slovenia.
  • Bruheim K; Department of Oncology, Oslo University Hospital, Oslo, Norway.
  • Rai B; Postgraduate Institute of Medical Education and Research, Department of Radiotherapy and Oncology, Chandigarh, India.
  • Cooper R; St James's University Hospital, Leeds Cancer Centre, Leeds, United Kingdom.
  • Van der Steen-Banasik E; Radiotherapiegroep Arnhem, Department of Radiotherapy, Arnhem, The Netherlands.
  • Wiebe E; Cross Cancer Institute and University of Alberta, Department of Oncology, Edmonton, Canada.
  • Pötter R; Department of Radiation Oncology, Comprehensive Cancer Center, Medical University, General Hospital of Vienna, Vienna, Austria.
  • Sturdza A; Department of Radiation Oncology, Comprehensive Cancer Center, Medical University, General Hospital of Vienna, Vienna, Austria.
  • Schmid MP; Department of Radiation Oncology, Comprehensive Cancer Center, Medical University, General Hospital of Vienna, Vienna, Austria.
  • Tanderup K; Department of Oncology, Aarhus University Hospital, Aarhus, Denmark.
  • De Leeuw A; Department of Radiation Oncology, University Medical Center Utrecht, Utrecht, the Netherlands.
  • Jürgenliemk-Schulz IM; Department of Radiation Oncology, University Medical Center Utrecht, Utrecht, the Netherlands.
  • Nout RA; Department of Radiotherapy, Erasmus MC Cancer Institute, University Medical Center, Rotterdam, the Netherlands.
Article in En | MEDLINE | ID: mdl-39278418
ABSTRACT

PURPOSE:

To provide risk estimations for vaginal morbidity with regard to vaginal dilation (summarizing the use of dilators and/or sexual activity) in locally advanced cervical cancer patients (LACC) treated with definitive radiochemotherapy and image-guided adaptive brachytherapy (IGABT) within the prospective, multi-institutional EMBRACE-I study. MATERIAL/

METHODS:

Physician-assessed vaginal morbidity (CTCAEv3.0), use of vaginal dilators and patient-reported sexual activity (EORTC-CX24) were prospectively assessed at baseline and during regular follow-up. Frequency analysis for vaginal dilation was performed in a sub-cohort of patients with ≥3 follow-ups. Regular dilation was defined if reported in ≥50% of follow-ups, no/infrequent dilation if reported in <50%. Actuarial estimates were calculated with Kaplan-Meier method; comparisons evaluated with the log-rank test. Univariate and multivariable Cox proportional hazard regression were used to evaluate risk factors for vaginal stenosis G≥2.

RESULTS:

The EMBRACE-I study included a total of 1416 patients (2008-2015); 882 were evaluated in the present report with a median follow-up of 60 months. Of those, 565 (64%) reported regular dilation. This was associated with a significantly lower 5-year risk of vaginal stenosis G≥2 compared to no/infrequent dilation (23% vs. 37%, p≤0.001). This univariate finding was confirmed by multivariable analysis, after adjusting for other risk factors (HR=0.630, p=0.001). Regular vaginal dilation was also associated with a significantly higher risk for vaginal dryness G≥1 (72% vs. 67%, p=0.028) and bleeding G≥1 (61% vs. 34%, p≤0.001).

CONCLUSION:

Vaginal stenosis represents irreversible fibrotic changes that can cause pain during gynecological examination and dyspareunia in LACC survivors. Regular vaginal dilation (defined as the use of dilators and/or sexual activity) is associated with a significantly lower risk for G≥2 vaginal stenosis, suggesting a potential improvement of vaginal patency. It is also associated with a significantly higher risk for mild G≥1 dryness and bleeding (no higher risk for G≥2), which both can be clinically managed.
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Int J Radiat Oncol Biol Phys / Int. j. radiat. oncol. biol. phys / International journal of radiation oncology, biology and physic Year: 2024 Document type: Article Country of publication: United States

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Int J Radiat Oncol Biol Phys / Int. j. radiat. oncol. biol. phys / International journal of radiation oncology, biology and physic Year: 2024 Document type: Article Country of publication: United States